ELOX

10.6900.38%
AE

Alan Edmund Walts

Independent Chairman

Dr. Alan Edmund Walts, Ph.D., serves as CEO and Chairman of Aleta Biotherapeutics since November 2025 and was previously its Executive Chairman from June 2025 to November 2025. He served as Board Observer and Business Advisor at Hemogenyx Pharmaceuticals Plc since July 2021. He is Venture Partner at Advent Life Sciences LLP since January 2014. He joined the firm in 2013. He joined as an Independent Director at Eloxx Pharmaceuticals, Inc. since April 01, 2021 and serves as its Chairman. He serves as an Executive Chairman at Zikani Therapeutics, Inc since May 2020 until April 2021. He is a Founding Board Member and serves as Executive Chairman and Treasurer of PIC Therapeutics Inc. He served as the Executive Chairman of Artax BioPharma Inc. since February 2017 until January 2024 and also has been its Advisor since July 2015. He serves as Director at Artax BioPharma Inc. He served as a Venture Partner of the life sciences team at Advent Venture Partners. He served as the Board Observer and Advisor at Amylyx pharmaceuticals, Inc. He is also a founder, Director and Treasurer of The Termeer Foundation, a public 501(c)(3) organization founded in 2019. Dr. Walts served as a Senior Vice President of Corporate Development at Genzyme Corporation. He is Founder at Arrakis Therapeutics, Inc. He has an industry experience in corporate venture capital, business development, research and development and general management at Genzyme Corporation. He is an advisor to Levicept, Inc. He served as Managing Director and Senior Advisor at Sanofi-Genzyme BioVentures. He joined Genzyme Corporation in 1986 as a Research Chemist and subsequently held a number of positions including Vice President of Research and Development, Program Director of Surgical Products, President and General Manager of Genzyme Pharmaceuticals LLC and served as Senior Vice President of Corporate Development. During his work in Corporate Development, he led strategic analyses and transactional activities related to Genzyme's Therapeutics business. Earlier, he led business and corporate development activities in Genzyme's Therapeutics business, where he initiated and executed a number of transactions and new business initiatives that led to several innovative marketed products. His roles at Genzyme Pharmaceuticals also included Head of chemistry and biopolymer research. He served as Chairman and Director at Aura Biosciences, Inc. He serves as a Director of 4s3 Bioscience. He served as a Director and business advisory of X4 Pharmaceuticals, Inc. He serves on the board of Arrakis Therapeutics, Inc. He is a Board Observer of KaloBios. He is currently an independent Director of Neuroelectrics Corp and a business advisor and board observer of several private companies including Amylyx Pharmaceuticals and Alpha Anomeric. He served as a Director of Peptimmune, Inc. since 2002. Previously, he served as a Director of Proteostasis Therapeutics, Inc. Dr. Walts also served as a Member of the Advisory Board of ALS Investment Fund. He has industry experience at Genzyme in business development, business strategy, research and development, general management and venture capital. Prior to leaving Genzyme in 2013, Dr. Walts most recently managed Genzyme's corporate venture fund, Genzyme Ventures (now Sanofi Ventures). Following Genzyme's landmark sale to Sanofi, he served as a business advisor to founding Chairman and CEO of Genzyme Henri Termeer from 2013 to 2017 and worked closely with Henri on founding and investing in early-stage companies. Dr. Walts is also an Advisor/Consultant to the Belinda A. Termeer Family Office, as of 2017. He completed the executive Program for Management Development at Harvard Business School in 1993. Dr. Walts holds a Ph.D. in Chemistry from Massachusetts Institute of Technology (MIT) in 1985 and then carried out Post-Doctoral Research in Biochemistry from Massachusetts Institute of Technology (MIT) with Professor Christopher Walsh and completed the executive Program for Management Development at Harvard Business School.

Positions